To assess the hemostatic consequences and antithrombotic effectiveness of blocking the platelet glycoprotein (GP) IIb/ila receptor for fibrinogen and other adhesive glycoproteins in vivo, well characterized murine monoclonal antibodies against the platelet GP Jib/lila complex, AP-2 and LJ-CP8, were infused intravenously into baboons. Four animals each received doses of 0.2, 0.4, and 1.0 mg/kg of purified AP-2 IgG, and three animals were given 1.0 mg/kg of the F(ab)2 fragment of AP-2. Five additional animals were given 10 mg/kg LJ-CP8 IgG. At the highest dose, radiolabeled AP-2 IgG bound to an average of 33,000 sites on the circulating platelets. Serial measurements included platelet count, bleeding time, platelet aggregation (induced by ADP, collagen, and 'y-thrombin), and "1In-platelet deposition onto Dacron vascular grafts. Bleeding times were markedly prolonged after injection of 1.0 mg/kg AP-2 IgG (19.2±3.4 min), 1.0 mg/kg AP-2 F(ab)2 (16.5±1.8 min), and 10 mg/kg LJ-CP8 (> 30 min) vs. control studies (4.6±0.2 min), and remained prolonged for 48 h. With each antibody platelet aggregation was initially reduced or absent, with partial recovery over 48 h in a manner that was inversely related to dose. AP-2, both whole IgG and F(ab)2 fragment, but not LJ-CP8, caused a dose-dependent reduction (20-46%) in the circulating platelet count over 24 h. Neither AP-2 nor LJ-CP8 caused a reduction in intraplatelet platelet factor 4, B-thromboglobulin, or I'4Ciserotonin. Graft-associated platelet thrombus formation was reduced by 73% (1.0 mg/kg AP-2 IgG and 10 mg/kg LJ-CP8) and 53% (1.0 mg/kg AP-2 F(ab)2) relative to control values. In contrast, neither heparin (100 U/kg) nor aspirin (32.5 mg/kg twice a day) showed antithrombotic efficacy in this model. Thus, antibodies that functionally alter the platelet GP JIb/lIla complex may produce immediate, potent, and transient, antihemostatic, and antithrombotic effects.
Introduction
Platelets bind fibrinogen and other adhesive glycoproteins, such as von Willebrand factor and fibronectin, following stimulation by appropriate physiologic agonists such as thrombin and ADP (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . As shown by studies in patients with Glanzmann thrombasthenia, who are deficient in membrane glycoproteins (GP)' Ilb and IIIa, and by studies in patients with severe afibrinogenemia, the inability of platelets to bind fibrinogen normally may result in significant platelet dysfunction that is characterized by prolonged bleeding and an abnormal aggregation response (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) . The crucial role of the platelet GP IIb/IIIa receptor has been further documented by a number of recent reports describing monoclonal antibodies that interact specifically with platelet GP Ilb and/or GP i11a, inhibit the binding of fibrinogen and other adhesive glycoproteins, and produce a thrombasthenic-like state in normal platelets in vitro (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) .
Based on these observations, it has been suggested that such antibodies may be useful as antithrombotic therapeutic agents (43, 44) . Preliminary studies in dogs with the F(ab')2 fragment of a murine monoclonal antibody to GP Ilb/Illa have shown dose-dependent inhibition ofADP-induced platelet aggregation ex vivo, and normalization of flow patterns in a platelet-dependent model of coronary artery stenosis. The antibody infusions were not associated with either spontaneous bleeding or marked thrombocytopenia, but relevant hemostatic measurements, such as the bleeding time, were not evaluated in these studies (43, 44) .
We have therefore used a baboon animal model to assess the effects of injected antibodies against platelet GP Ilb/IIIa with respect to the following variables: platelet count, bleeding time, platelet aggregation, content of platelet storage granules, and platelet deposition onto Dacron vascular grafts. A baboon animal was used in this study since this species is hemostatically similar to man with respect to coagulation factors, platelets and their granular contents, and immunologic characteristics of platelet and plasma proteins as studied using human radioimmunoassays (45) (46) (47) (48) . The antithrombotic efficacy of injected antibody was assessed using a gamma scintillation camera to measure "'In-platelet deposition onto Dacron vascular grafts incorporated acutely into an externalized femoral arteriovenous shunt. This method was chosen since the measurements of platelet incorporation into forming arterial thrombus are quantitative and reproducible, and since the graft materials used have clinical applications in man (48) . These studies indicate that the administration of antibodies that block the platelet GP antibody distribution and kinetics in vivo. Six additional animals were given either the combination of heparin (100 U/kg; Abbott Laboratories, North Chicago, IL) plus oral aspirin (32.5 mg/kg twice daily, Sigma Chemical Co., St. Louis, MO), or aspirin alone at this dose (five animals).
The animals weighed [8] [9] [10] [11] [12] kg and had been observed to be disease-free for at least 6 wk before use. All animals had a chronic arteriovenous (A-V) shunt surgically implanted between the femoral artery and vein. Ketamine hydrochloride (10 mg/kg, i.m.) was given as a preanesthetic agent, and the operation was (47, 48, 62) . When used, Dacron vascular grafts were subsequently interposed between the segments of the permanent A-V shunt.
Platelet count and hematocrit determinations were performed on whole blood collected in 2 mg/ml disodium EDTA using a J. T. Baker (model 810; Allentown, PA) whole blood analyzer. Before the antibody studies, whole blood platelet counts averaged 370,000±86,000 platelets/,Ml (± 1 SD) and hematocrits averaged 34±5%. Bleeding time measurements were performed on the shaved volar surface ofthe forearm using the standard template method as previously described for studies in baboons (49) . Bleeding time measurements were performed in duplicate and were averaged.
Antibody preparation and characterization. The preparation and characterization of AP-2 has been reported (37) . LJ-CP8 was prepared and characterized by methods described previously (50) , with the only modification that human washed platelets used as immunogen were treated with chymotrypsin (51) before injection. LJ-CP8 reacted with GP lIb and/or GP lIla when the two were in complex, as shown by (a) its lack of reactivity with platelets from patients with Glanzmann thrombasthenia; (b) solid-phase immunoisolation studies (50, 52) demonstrating that the antibody bound to the complex of two platelet membrane proteins having the electrophoretic mobility of GP Ilb and GP IlIa (53); (c) lack of reactivity with normal platelets incubated with 5 mM EDTA for 15 min at 37°C (54, 55) . LJ-CP8 and AP-2 were of the IgG, subclass. Purified IgG was prepared from ascitic fluid as previously described (50) . Bivalent F(ab)2 fragments were prepared from AP-2 IgG by papain digestion as described (56 15 Atm ADP was reduced 50% (two studies).
Platelet aggregation studies. Platelet aggregation was measured using an aggregometer (Chrono-Log, Havertown, PA) by recording the increase in light transmission through a stirred suspension of PRP maintained at 370C. Platelet-rich and platelet-poor plasmas were prepared as previously described (49 . This procedure produced impervious grafts rigidly constrained to a linear geometry, and having an inner diameter of precise dimensions (4.0 mm). The resulting flow channel was smooth in its transition from the Silastic to the graft without imperfection due to the coupling procedure. The avoidance of a hemodynamic "step" at the graft junctions has been found essential to insure reproducible and uniform platelet deposition following blood exposure (48) . The 4.0-mm i.d. Silastic tubing segments proximal and distal to the Dacron graft were subsequently connected to the 3.0 mm i.d. Silastic tubing comprising the chronic arteriovenous shunt with 2 cm long tapered Teflon connectors (Small Parts, Inc.). Mean blood flow rates through vascular graft segments incorporated into the A-V shunt system were measured continuously using a Doppler ultrasonic flowmeter (L and M Electronics, Daly City, CA) and "C" shell cuff type transducer probe that fitted snugly around the Silastic tubing comprising the chronic shunt. In all studies initial blood flow rates ranged from 160 to 240 ml/min.
Grafts were initially placed and imaged I h after the injection of autologous "'.Iin-labeled platelets. Antibodies were injected on the following day. Subsequent grafts were placed 10 min after the antibody was infused. When heparin and aspirin were given, grafts were placed 10 min after intravenous heparin administration. In studies with aspirin, grafts were placed 1 h after the first dose given on the second day of administration. In all studies the grafts were placed for 1 h and then removed.
Platelet labeling with ["'In]oxine and ["C]serotonin. Autologous baboon blood platelets were labeled with ["'Injoxine as previously described (48) . In brief, whole blood (100 ml) was collected directly into plastic bags (TA-3; Fenwal Laboratories, Deerfield, IL) containing 20 ml acid-citrate-dextrose anticogaulant (NIH formula A). The blood was centrifuged in the bag at 300 g for 10 min. The supernatant PRP was transferred to a second bag and pH adjusted to 6.5 by the addition of 0.15 M citric acid (0.1 ml/ 0 ml PRP). The red blood cell fraction was returned to the donor animal. The platelets were formed into a pellet by centrifugation of the PRP at 1,300 g for 15 min. The supernatant platelet-poor plasma (PPP) was completely decanted and discarded. To remove residual plasma proteins, the bag containing the platelet pellet was carefully washed once by overlaying with 30 ml of Ringer citrate dextrose (RCD; pH 6.5) which was decanted and dis- population is functionally normal as demonstrated by equivalent reductions in circulating platelet count and circulating platelet radioactivity in response to infused collagen suspensions or blood exposure to vascular grafts (48, 62) .
In five additional studies, platelets harvested according to the same method were simultaneously labeled with 500 ,ACi of ["'In]oxine and 20 1ACi of ['4C]serotonin as described previously (63) . These studies were included to examine the possibility that platelet granular serotonin might be preferentially lost as compared to the cytoplasmic "'Inplatelet label. To determine the platelet radioactivities, serial 3.0-ml blood samples were harvested twice by the addition of 5.0 ml RCD and centrifugation at 250 g for 5 Platelet survival studies. After platelet labeling with "'In, 3-ml blood samples were taken at daily intervals for 4 d, and then counted using a gamma spectrometer. Mean platelet life span was determined by computer least-squares fitting the disappearance data to gamma functions as described previously (47, 48) .
Measurement of platelet factor 4 (PF-4) and fl-thromboglobulin (fl-TG). The platelet contents of PF-4 and ,B-TG were measured by radioimmunoassay of Triton X-100 platelet lysates as previously described (48) . Plasma levels of PF-4 and ,B-thromboglobulin (,B-TG)
were also determined by radioimmunoassay on blood samples collected and processed as described previously (48 (Fig. 2 B) . Values were significantly prolonged at 24 h (12.6±0.9 min; P < 0.001), and modestly prolonged at 48 h (8.8+1.8; P = 0.07).
In vivo distribution of '311-labeled AP-2 IgG. The time course of platelet and plasma radioactivity after the injection of "3'I-labeled AP-2 IgG is shown in Fig. 3 . At the highest dose of "3'I-labeled antibody, 1.0 mg/kg, -33,000 molecules per platelet were initially bound (Fig. 3 A) . With 0.2 and 0.4 mg/kg IgG, 10,000-15,000 sites per platelet were initially occupied. In all cases, platelet associated IgG decreased progressively to < 2,000 molecules per platelet after 4 d. Thus, it is apparent that platelets bearing anti-GP Ilb/11a antibodies circulated for hours. Analysis by polyacrylamide gel electrophoresis revealed that the platelet-bound radioactivity was indeed associated with intact IgG molecules (Fig. 3) .
Plasma AP-2 levels ranged from 0.5 to ,tg/ml after the injection of 0.2 and 1.0 mg/kg, respectively. Most of the plasma IgG was cleared within the first 24 h, with a more gradual reduction to < 0.5 ,ug/ml by 96 h. Studies with Dacron vascular grafts. Measurements of platelet deposition onto Dacron grafts inserted 10 min after the injection ofAP-2 antibodies, and exposed for 1 h, are given in Fig. 4 . Control studies were performed in 17 animals subsequently given either AP-2 IgG (nine animals), AP-2 F(ab)2 (three animals), or UJ-CP8 (five animals). Since we have previously shown that graft platelet deposition depends in an approximately linear fashion on the circulating platelet count (65) , the experimental groups were chosen to have comparable mean platelet counts in the range 307,000 to 389,000 plate- lets/yl (Fig. 4) . After 60 min of blood exposure, AP-2 IgG reduced graft platelet deposition in a dose-dependent fashion. Thus deposition was reduced by an average of 41% by 0.2 mg/kg AP-2 (P < 0.1 vs. controls), 5 1% by 0.4 mg/kg AP-2 (P < 0.01), and 73% by 1.0 mg/kg AP-2 (P < 0.001). Platelet While the results obtained with Dacron grafts evaluated on subsequent days following AP-2 infusion were ambiguous due to the observed reductions in ciruclating platelet count (Table  I) , platelet counts were relatively stable after LJ-CP8 administration. Thus 24 h after LJ-CP8 injection, platelet accumulation onto freshly inserted grafts in four animals averaged 7.5±2.22 X 109 platelets per graft at 1 h, and was reduced by 66% vs. control studies (P < 0.01, paired t test). In two animals studied at 48 h, graft platelet deposition was still reduced by an average of 46% after the 1-h exposure period.
Three additional groups of animals were also studied following administration of heparin (100 U/kg), oral aspirin (32.5 mg/kg twice daily) or the combination of heparin and aspirin at three doses. These study groups had comparable mean circulating platelet counts, ranging from 365,000 to 450,000 platelets/ul. Neither heparin, aspirin, nor the combination was effective in reducing platelet deposition over the (Table  IV) . Similarly, platelet ['4C]serotonin radioactivity, expressed as a percentage of pre-IgG values, was not preferentially reduced relative to platelet cytoplasmic "'In radioactivity. Also, 2 h after the injection of 1.0 mg/kg AP-2 IgG into three animals, plasma levels ofPF-4 and f,-TG averaged 4.1 ± 1.8 ng/ml and 1.8±0.4 ng/ml, respectively, and were equivalent to control values obtained in untreated animals as reported previously (48) . These results suggest that the circulating platelets had not undergone either a-granule or dense granule release, and are also in accord with the observed inability of AP-2 IgG to induce platelet release in vitro (see Methods). Platelet survival studies. Determination ofplatelet survival was not appropriate in animals given AP-2 IgG or F(ab)2 since these antibodies caused marked fluctuations in the circulating platelet count. Although platelet counts were largely unchanged following administration of LJ-CP8, this result did not preclude the possibility of some increase in platelet turnover. Therefore, in two animals platelet survival was measured over 4 d after injection of 10 mg/kg IJ-CP8. To maintain a normal platelet count over the study interval, no blood was drawn for other assays, nor were graft thrombosis studies conducted. The mean platelet lifespans averaged 5.24 and 5.18 d, values that were normal for baboons as previously reported (48) .
Discussion
The results of the present study in baboons demonstrate that infusion of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex may significantly impair both platelet hemostatic function and the ability ofplatelets to participate in thrombus formation on arterial Dacron vascular grafts. In general, the time course and dose dependence of the effects of infused antibodies were similar for measurements of platelet aggregation, bleeding time, and graft platelet deposition. Interestingly, the lowest dose of AP-2 IgG (0.2 mg/kg) caused a transient impairment ofplatelet aggregation but had no detectable effect on bleeding time (Fig. 2) . Similarly, in animals given 0.4 mg/kg AP-2 IgG, bleeding times at 24 h were normal, but aggregation in response to all three agonists was still reduced. These results suggest that, at least under some conditions, measurements of abnormal platelet aggregation ex vivo do not necessarily predict platelet hemostatic function in vivo.
The prolonged bleeding times observed in the present study are in agreement with the bleeding tendency consistently observed in patients with Glanzmann thrombasthenia who lack platelet GP Ilb and IlIa, and whose platelets are unable to normally bind fibrinogen and other adhesive glycoproteins such as von Willebrand factor and fibronectin (1, (19) (20) (21) (22) (23) (24) (25) (26) (27) . Previous investigators using a dog model have observed that infusion of an antibody against platelet GP IIb/IIIa did not cause spontaneous bleeding (43, 44) . However, since spontaneous bleeding is usually associated only with severe and prolonged thrombocytopenia or profound inhibition ofplatelet function, hemostatic effects may have been inadequately evaluated in these studies.
In this report we observed comparable dose-dependent reductions in platelet count following injections of both AP-2 IgG and AP-2 F(ab)2 fragments. Thus, the mechanism underlying the fall in platelet count was independent of the Fc portion of the molecule. Previous studies performed in a limited number of dogs given F(ab')2 antibody fragments (43) showed no significant effect on platelet count. Since different animals and different antibodies were used in these studies it is unwarranted to draw firm conclusions regarding mechanisms on the basis of this comparison, particularly since injection of whole IgG molecules of antibody IJ-CP8 had no effect on platelet count or platelet lifespan, even when given at doses 10 times greater than AP-2. Therefore, the relative merits of using whole IgG or Fab fragments may depend in each case upon the effects of individual antibodies on platelet viability, and on the feasibility of preparing Fab fragments.
Both AP-2 IgG and LJ-CP8 inhibited fibrinogen binding to baboon platelets, the former partially and the latter completely. Maximal effect was obtained with saturating amounts of antibody, and the results of in vitro inhibition studies were used to calculate the amount of antibody to be injected for in vivo experiments. The fact that AP-2 causes only partial inhibition of fibrinogen binding to baboon platelets in vitro is noteworthy, since it demonstrates that even partial blockade of the GP IIb/IIIa receptor may cause significant inhibition of platelet function in vivo. At the highest dose of AP-2 used in this study, 1 .0 mg/kg, -33,000 sites per baboon platelet were occupied, in reasonable agreement with the number of GP IIb/IIIa molecules per human platelet (3, 7, 32, 37, 66, 67) . Also, AP-2 concentrations that effectively inhibit fibrinogen binding in vitro, > 2 ,ug/ml, are in good agreement with the effective plasma levels achieved in vivo, i.e., 2-10 ,g/ml (Fig. 3) (37). Based on a baboon blood volume of 70 ml/kg and a molecular weight of 160,000 for the monoclonal IgG, it can be calculated from the data shown in Fig. 3 A that following the injection of 0.2, 0.4, and 1.0 mg/kg, respectively, -59, 34, and 25% of injected IgG molecules were initially bound to platelets. We also found that intact heavy and light chain constituents of IgG molecules were associated with the platelet for up to 96 h. This lack of processing clearly suggests that the IgG remained bound to the platelet surface and was not internalized.
The acute thrombosis model used in the present studies, involving the acute interposition of Dacron vascular grafts into arteriovenous shunts, has been previously described (48) . This model was chosen for several reasons. First, this system permits control of relevant physical variables such as blood flow rate and graft geometry. Second, measurements by external gamma camera imaging are quantitative and reproducible without attenuation of emissions due to intervening tissues. Third, anticoagulants are not required so that forming thrombi are subject to normal filtration, dilution, and inactivation mechanisms in the animal.
Using this model, marked reductions in graft platelet deposition were demonstrated for both antibodies studied. Interestingly, intermediate doses of AP-2, i.e., < 0.4 mg/kg, showed significant effects on platelet deposition without prolonging the bleeding time to a degree likely to be of clinical consequence (e.g., > 10 min). In contrast, neither heparin (100 U/kg) nor aspirin (32.5 mg/kg twice daily) showed antithrombotic efficacy. At these doses, heparin has been shown to prevent the accumulation of morphologically identifiable amounts of fibrin onto vascular grafts (68) , and aspirin has been shown to reduce the capacity of platelets to synthesize thromboxane A2 (TxA2) to < 1% of control values (47) . Thus, in this setting ofacute arterial thrombosis associated with prosthetic vascular grafts, blocking the platelet GP IIb/IIIa receptor was substantially more effective than conventional therapies directed against coagulation-or thromboxane-mediated pathways of platelet recruitment. Interestingly, ticlopidine, a potent antiplatelet agent that induces a thrombasthenic-like state in platelets by mechanisms not clearly defined (69) , has also been shown to be efficacious in this model (65) . However, ticlopidine requires several days of pretreatment to reach full effectiveness, and these effects persist for several days following discontinuance of therapy.
Finally, a number of monoclonal antibodies against platelet glycoproteins have been described which differ markedly with respect to their effects on platelet function in vitro (31-33, 36, 37, 41, 42, 50, 70) . Given the possibility that such antibodies could exhibit differential effects on thrombosis vs. hemostasis, or may differ in their capacity to induce immunemediated platelet removal, further studies are warranted. Such antibodies might be particularly attractive as antithrombotic agents in situations requiring immediate, potent, yet transient inhibition of platelet function in vivo, such as small caliber vascular grafts, percutaneous arterial angioplasty, or post-reperfusion arterial occlusion.
